Classification
Classification of arthritis in childhood has not been satisfactory up to recent years. We all realize that juvenile rheumatoid arthritis (JRA) is not a single homogeneous disease, but for years different criteria have been used in different countries. Under the auspices of the World Health Organization (WHO) and the International League of Associations for Rheumatology (ILAR), a Task Force for Classification Criteria has been established, and two sets of classification criteria have been generated. The descriptive term "juvenile idiopathic arthritis" was adopted as an umbrella term to indicate disease of childhood onset characterized primarily by arthritis of no known etiology persisting for at least 6 weeks.
In the 1997 revised (Durban) criteria, seven categories were described, with specific characteristics, exclusions, and descriptors for each category [1] . It is not yet clear whether this classification system is completely satisfactory, or if it provides substantial advantage over the previous ones. Clinical studies performed internationally by independent observers and validation of homogeneity within categories will, it is hoped, shed more light into a field that has been, and partly still is, very confusing. It is likely that until the etiology and pathogenesis of the disease(s) will be elucidated the work will always be in progress.
Epidemiology
Andersson Gare, in a recent review [2••], discussed current data on incidence and prevalence of JRA. These data vary greatly among published studies, because of differences in classification criteria, methodology for case identification and ascertainment, and definition of study population. In studies that use similar methodology an incidence of 5-18 and a prevalence of 30-150 per 100,000 children under the age of 16 are found in Europe and on the American continent.
In a field study, Ozen et al.
[3] screened more than 46,000 children in Turkey, with a well planned and performed study design in which all children suspected for the diagnosis were examined by trained pediatricians. They found chronic arthritis (including ankylosing spondylitis and psoriatic arthritis) in 64/100,000. Of note, only 12 of the 30 defined children had already been diagnosed by a physician, confirming the importance of a correct physical examination by trained personnel and the pitfalls of epidemiologic studies 415
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Epidemiologic surveys on uveitis in JRA have been rare, with great variations in prevalence among different series. In a population-based study in Finland [4], patients were identified from the nationwide sickness insurance scheme, that entitles them to receive reimbursement for medication and provides a good basis for epidemiologic studies. A total of 18 patients with uveitis out of 114 JRA patients was found (16%).
A seasonal variation of systemic JRA could help to clarify an infectious cause, but a multicenter study performed in Israel [5] failed to prove any seasonal pattern.
Pathogenesis
Juvenile rheumatoid arthritis has been termed a "a complex genetic trait" by Glass and Giannini [6••] . In this excellent review the authors have summarized current knowledge on the genetics of JRA, pointing out that gene-gene interactions are likely to influence the development of disease. The study of epidemiologic and demographic issues such as sex predominance, disease occurrence variations over time, and familial disease can contribute to the understanding of how, when, and why the disease develops.
Presentation of antigenic peptides by HLA can play a role in disease immunopathogenesis. A nationwide study of HLA class II associations was performed in Greece on 223 patients, who were classified into different groups and subgroups [7•]. The controls were 98 healthy, unrelated, age-matched subjects of the same ethnic background. The DQA1*0501 allele was found to be associated with different JRA groups/subgroups. The haplotype DRB1*13, DQB1*0301 was strongly associated with uveitis, and the presence of DRB1*13 or DRB1*0201 conferred susceptibility to uveitis independently, with a stronger association in the presence of both alleles. No specific allele was found to be associated with systemic arthritis, presence of antinuclear antibodies (ANA), psoriatic lesions, or severity of arthritis.
Feichtlbauer et al.
[8] analyzed microsatellite polymorphisms located in the major histocompatibility complex (MHC) region in a large series of early-onset pauciarticular JRA patients (N = 177) and controls (N = 157), in order to find loci other than HLA-A, HLA-DRB1, HLA-DQA1, or HLA-DQB1 that might be involved in the coding for disease susceptibility. However, no evidence of further microsatellite associations was found, suggesting that the HLA genes themselves may be directly involved in pathogenesis.
Although classical immunogenetic studies have focused on the MHC, there is now evidence that other, non-MHC genes, might contribute to disease pathogenesis. For example, Crawley et al. [9••] provided evidence that the tendency to cytokine imbalance in JRA might be genetically determined.
In particular, the authors showed that polymorphic haplotypes of the interleukin (IL)-10 5' flanking region determine variable IL-10 transcription, and that particular haplotypes are associated with different JRA phenotypes. It is speculated that lower endogenous production of IL-10 would lead to a more severe form of disease such as extended oligoarthritis. These interesting findings, if confirmed in other patient populations and with other methodologies, might have a clinical impact as well, in that therapeutic interventions with an exogenous anti-inflammatory cytokine such as IL-10 could be tailored to selected cases.
Major histocompatibility complex associations have been confirmed more consistently than non-MHC associations in multiple series. In fact, McDowell et al. [10] identified an IL-1α promoter polymorphism which was found to be strongly associated with uveitis in Norwegian patients with pauciarticular JRA, but Donn et al. [11] were not able to reproduce these findings in 164 white patients with pauciarticular JRA from the UK.
Beside imbalances in the cytokine network, immunologic abnormalities in JRA include the production of autoantibodies such as ANA. The detection of ANA still has to depend on immunofluorescence, because although current ELISA tests could be advantageous in that they are highly reproducible and require less effort and lower costs, have been shown to be less useful than immunofluorescence in a comparison study of 178 JRA patients [12] . Obviously, many of the nuclear antigens that give rise to reactivity at immunofluorescence still have to be identified.
Several studies on the prevalence of other autoantibodies in JRA have been recently performed. Antineutrophil cytoplasmic antibodies (ANCA) have been searched for in sera from patients with JRA in a study from the Czech Republic [13] and another from Turkey [14] . Positivity was found in 21/78 patients (27%) in the first study and in 14/31 (45%) in the second. Staining at immunofluorescence was p-ANCA in all cases but one, with positive ELISA for antimyeloperoxidase in only a minority of the positive sera. Similarly, anticardiolipin antibodies were studied by two different groups, one in Brazil [15] and one in the US [16] . In the first study, overall positivity was 32.5%, and in the second 7%; however, antibody levels were usually at low titers, and no association with the clinical features of the antiphospholipid syndrome was observed. Finally, another Brazilian study [17] of 86 JRA patients searched for the presence of circulating antiperinuclear factor and antibodies to the stratum corneum of rat esophagus, finding prevalences of 49% and 2%, respectively. Although these studies are important, none of these antibodies should be used to make or support a diagnosis that is essentially a clinical one, contrary to what has been stated by some of these authors.
A relation exists between the endocrine and immune system in autoimmune disorders. In particular, prolactin has immunomodulatory effects, and Picco et al. [18] have found elevated serum prolactin concentrations in prepubertal girls with pauciarticular JRA in clinical remission. The authors showed a direct correlation between prolactin and IL-6, but not tumor necrosis factor receptor levels, and speculated on possible functional relations between prolactin and IL-6. The interactions between endocrinology and immunology are still an open field of study.
Clinical features
Sharma et al. [19] reported the joint distribution at presentation in children with pauciarticular JRA. A total of 215 children with pauciarticular arthritis, 171 girls and 44 boys, were selected for the study. The knee and ankle were the most commonly affected joints, whereas the shoulders were rarely involved. The small joints of the hands were the third group of joints affected, followed by the small joints of the feet. Interestingly, the risk for uveitis in the group with arthritis of small joints has been found to be comparable to those with large joint arthritis.
The association between chromosomal abnormalities and JRA has been previously reported. Turner syndrome (TS) is frequently associated with autoimmune disorders, including JRA. Wihlborg et al. [20] described three additional cases of TS associated with JRA. The purpose of this work was to alert radiologists to recognize the radiographic bone changes of chronic joint disease in girls with TS, and conversely to suspect TS in girls with JRA and metacarpal shortening.
Arthritis mutilans is characterized by severe joint deformities of the hands. Fingers are shortened with hypermobile joints, and radiographically severe resorption of joint and bone commencing at the articular side is found.
Belt et al.
[21] evaluated 22 patients with polyarticular JRA (9 rheumatoid factor-positive and 13 rheumatoid factor-negative), all with hand deformities. Severe resorptive changes were present in most metacarpophalangeal and proximal interphalangeal joints, leading to unstable and shortened digits. The authors introduce a new radiographic definition for arthritis mutilans. 
Treatment
Several studies evaluated the effectiveness and safety of different treatments in JRA. Autologous or allogeneic bone marrow transplantation has recently emerged as a possible therapy in rheumatic diseases. Wulffraat et al. [23••] reported the first experience on autologous hemopoietic stem-cell transplantation (AHSCT) in patients with severe JRA who had not responded to disease-modifying antirheumatic drugs. Four children, one affected by systemic and three by polyarticular JRA, underwent AHSCT. Treatment was well tolerated and induced remission in all patients. Complete normalization of erythrocyte sedimentation rate, CRP,and hemoglobin levels was achieved by 6 weeks, and a drug-free follow-up of 6-18 months with a marked decrease in joint swelling, pain, and morning stiffness was observed. Despite Tcell depletion, a rapid immune reconstitution in three of the four children was observed. Methotrexate (MTX) and cyclosporin were stopped before AHSCT in all patients, and steroids were tapered and withdrawn two months after. Short-term results in these patients are promising, but a prolonged follow-up is required to draw firm conclusions.
Quartier et al.
[24] report a life-threatening complication of AHSCT in a 9-year-old girl affected by refractory systemic juvenile chronic arthritis (JCA). A lethal diffuse alveolar syndrome caused by Toxoplasma gondii infection occurred during the conditioning period, and disseminated toxoplasmosis was revealed by necroscopy.
The occurrence of dreadful complications such as this must be considered in all children with chronic rheumatic diseases and immunosuppressive treatment who undergo bone marrow transplantation. The rationale for AHSCT and the efficacy are still uncertain, and mortality risk is high. A standardized protocol with strict inclusion criteria is advocated, and the risks and benefits of this procedure have to be carefully balanced.
Ten years of experience with MTX have confirmed the efficacy and the safety of this drug in JRA. Adverse effects have been reported in about 42% of children, and monitoring of liver function tests is required. In order to determine risk factors for MTX toxicity and laboratory variables at baseline that could predict clinical efficacy of the drug, 80 children with JRA treated with MTX were retrospectively studied by Ravelli et al. [25] . Patients with extended pauciarticular arthritis were more likely to achieve disease control by MTX therapy, even though an early relapse was observed in this group after drug discontinuation. Thrombocytosis (indicator of systemic inflammation) was the only significant risk factor for liver biochemical abnormalities.
Growth retardation is a common complication of JRA, and occurs more frequently in children treated with steroids. Simon et al. [26] reported the efficacy and safety of growth hormone (GH) therapy in 14 children with systemic/polyarticular JCA receiving long-term treatment with corticosteroids (mean height, 4.3 standard deviation score (SDS), height velocity, 5.1 SDS). GH was administered at the dosage of 1.4 IU/Kg/wk for 1 year: mean height velocity increased from 1.9 to 5.4 cm/yr. This study confirms previous findings: GH may counteract the adverse effects of glucocorticoids on growth and metabolism in patients with JRA. However, after the period of treatment height velocity fell to pretreatment values, and height SDS at the end of the second year was lower than before treatment.
Savoilanen et al. [27] reported good results on 79 consecutive patients with refractory JCA treated with chlorambucil; however, no details on inclusion criteria were given, and the study appears to be somewhat retrospective. Moreover, many serious complications occurred, including two lethal cases of leukemia. We believe that this drug might have a role in JRA only for amyloidosis, a complication much more common in Europe than in the US, especially if the inflammation is not controlled by second-line drugs. Outcome Ruperto et al. [29] examined the responsiveness of the disease activity measures commonly used in clinical trials. Physician and parent global assessment were the more responsive instruments; erythrocyte sedimentation rate, CRP, functional status measures and articular variables showed intermediate responsiveness, whereas morning stiffness and hemoglobin and platelet count were the least responsive instruments. The authors conclude that subjective estimations of disease activity, either by physicians or parents, are the most responsive instruments in the assessment of the therapeutic response in children with JCA.
Pregnancy may influence the course of connective tissue diseases, and data on fertility and disease outcome in JRA are limited. A recent study from Poland [30•] performed on 39 adult women who suffered from early-onset pauciarticular JCA suggests that pregnancy generally has a good outcome and induces amelioration of disease activity. However, a flare of disease often appears after delivery. This behavior is similar to that of rheumatoid arthritis but different from the spondyloarthropathies and systemic lupus erythematosus, where disease activity either does not change or worsens during pregnancy.
Conclusions
Many issues in the pathogenesis and treatment of JRA have been addressed in the studies covered by this review. Basic and clinical research are advancing, with outstanding results that will open new therapeutic fields, whereas studies on classification and outcome will help in performing studies on homogeneous populations and in determining the efficacy of treatments.
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